肿瘤药学Issue(4)：288-292,5.DOI:10.3969/j.issn.2095-1264.2015.04.11
局部晚期乳腺癌术后同步放化疗耐受性的临床观察
Clinical Observation of the Tolerability of Synchronous Chemoradiotherapy after Surgery in Treatment of Locally Advanced Breast Cancer
摘要
Abstract
Objective To observe the toxicity of synchronous chemoradiotherapy and sequential schedule as adjuvant therapy after surgery for locally advanced breast cancer, and to evaluate the feasibility of synchronous chemoradiotherapy. Methods Eighty-three patients with prior breast surgery and histologically confirmed locally advanced cancer were included in this study. They received adjuvant chemotherapy FEC ( Fluorouracil, epirubicin and cyclophosphamide) followed by T (docetaxel). They were randomly divided into two groups and received synchronous chemoradiotherapy with docetaxel (42 cases) or sequential schedule (41 cases), respectively. Their clinical toxic reactions were assessed after all schedules. Results All patients finished all schedules. Compared with sequential group, the adjuvant therapy time in synchronous group reduced 5.4 weeks on average. The rates ofⅢ~Ⅳdegrees of gastrointestinal reactions or bone marrow had no significant difference (P>0.05). Conclusions Synchronous chemo-radiotherapy can shorten the treatment time for locally advanced breast cancer after surgery as an adjuvant therapy. It is a well-tolerated regimen, and had no effect on adjuvant chemotherapy process. Therefore, it is worth of further observation.关键词
乳腺癌/化疗/放射治疗Key words
Breast cancer/Chemotherapy/Radiotherapy分类
医药卫生引用本文复制引用
杨慧,黄海欣,陆颖,李桂生,黄东宁..局部晚期乳腺癌术后同步放化疗耐受性的临床观察[J].肿瘤药学,2015,(4):288-292,5.基金项目
自筹经费科研（编号Z2014394）。 （）
